Patents by Inventor Patrick Finn

Patrick Finn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242899
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Application
    Filed: February 14, 2022
    Publication date: August 4, 2022
    Inventors: Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
  • Publication number: 20220195026
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Application
    Filed: December 23, 2021
    Publication date: June 23, 2022
    Applicant: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Patent number: 11279725
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: March 22, 2022
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 11242384
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 8, 2022
    Assignee: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Publication number: 20220000856
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Application
    Filed: June 22, 2021
    Publication date: January 6, 2022
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lutjens, Terry Patrick Finn
  • Publication number: 20210244803
    Abstract: The present application provides methods of treating Pompe disease such as infantile-onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid ?-glucosidase (GAA) conjugate, such as avalglucosidase alfa. Also provided are formulations of the oligosaccharide-GAA conjugates.
    Type: Application
    Filed: February 8, 2021
    Publication date: August 12, 2021
    Inventors: Kristina AN HAACK, Patrick FINN
  • Patent number: 11071729
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: July 27, 2021
    Assignees: Addex Pharmaceuticals S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Terry Patrick Finn
  • Publication number: 20210171942
    Abstract: The present disclosure relates to methods and kits for DNA library construction, particularly for consistent and reproducible DNA sequencing.
    Type: Application
    Filed: December 21, 2020
    Publication date: June 10, 2021
    Applicant: ArcherDX, LLC
    Inventors: Patrick Finn, Greg Patton, Hongbo Liu
  • Publication number: 20210040456
    Abstract: This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.
    Type: Application
    Filed: November 21, 2018
    Publication date: February 11, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Raj Rajendran, Patrick Finn, Paolo G.V. Martini, Ding An, Athanasios Dousis, Kanchana Ravichandran
  • Publication number: 20200399358
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Application
    Filed: July 16, 2020
    Publication date: December 24, 2020
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Patent number: 10870847
    Abstract: The present disclosure relates to methods and kits for DNA library construction, particularly for consistent and reproducible DNA sequencing.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 22, 2020
    Assignee: ArcherDX, LLC
    Inventors: Patrick Finn, Greg Patton, Hongbo Liu
  • Publication number: 20200299652
    Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 24, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G.V. Martini, Vladimir Presnyak, Patrick Finn
  • Patent number: 10766955
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 8, 2020
    Assignee: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Publication number: 20200216485
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Application
    Filed: September 24, 2019
    Publication date: July 9, 2020
    Inventors: Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
  • Publication number: 20200038391
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lutjens, Terry Patrick Finn
  • Patent number: 10464962
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 5, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 10328218
    Abstract: A nebulizer system includes a body having a fluid chamber and an aerosol chamber, and a vibrator assembly positioned at an interface between the fluid chamber and the aerosol chamber. The vibrator assembly may include a diaphragm, having a fluid side and an aerosol side, defining a plurality of perforations between the fluid side and the aerosol side, and one or more vibrator elements operatively associated with the diaphragm to vibrate the diaphragm to produce aerosolized medicament projected into the aerosol chamber from the plurality of perforations. Each perforation of the plurality of perforations projects the aerosolized medicament along a respective projection path relative to a plane defined by the aerosol side of the perforation, the one or more vibrator elements or the diaphragm support substrate further being configured to angularly displace the aerosol side of the diaphragm to sweep the direction of at least one projection path.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 25, 2019
    Assignee: ENGINEERED MEDICAL SYSTEMS, INC.
    Inventors: George Ashford Reed, Jeffrey John Quinn, Brad Hayden Quinn, Patrick Finn Boileau
  • Publication number: 20190078084
    Abstract: The present disclosure relates to methods and kits for DNA library construction, particularly for consistent and reproducible DNA sequencing.
    Type: Application
    Filed: April 4, 2018
    Publication date: March 14, 2019
    Applicant: ArcherDX, Inc.
    Inventors: Patrick Finn, Greg Patton, Hongbo Liu
  • Publication number: 20190062416
    Abstract: A method of treating primary focal segmental glomerulosclerosis in a patient having an APOL1 variant, comprising intravenously administering a TGF? antagonist to the patient.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 28, 2019
    Applicant: GENZYME CORPORATION
    Inventors: Steven R. Ledbetter, Sara Engstrand, Patrick Finn, Julie Lin, Robert John Pomponio
  • Publication number: 20180244763
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Application
    Filed: January 19, 2018
    Publication date: August 30, 2018
    Applicant: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu